You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDeferasirox
Accession NumberDB01609
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionDeferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. It is the first oral medication approved in the USA for this purpose.
Structure
Thumb
Synonyms
Deferasiroxum
Exjade
ICL 670
ICL 670a
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ExjadeTablet, for suspension125 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated360 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension125 mgOralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mg/1OralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeTablet, film coated180 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated360 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated90 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
ExjadeTablet, for suspension125 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mg/1OralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeTablet, film coated180 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated360 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mgOralNovartis Pharmaceuticals Canada Inc2006-11-10Not applicableCanada
ExjadeTablet, film coated90 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension250 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension125 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, film coated180 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension125 mg/1OralNovartis Pharmaceuticals Corporation2005-11-30Not applicableUs
ExjadeTablet, film coated90 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
ExjadeTablet, for suspension500 mgOralNovartis Europharm Limited2006-08-28Not applicableEu
JadenuTablet, film coated360 mg/1OralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
JadenuTablet180 mgOralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
JadenuTablet360 mgOralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
JadenuTablet, film coated90 mg/1OralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
JadenuTablet90 mgOralNovartis Pharmaceuticals Canada Inc2016-03-24Not applicableCanada
JadenuTablet, film coated180 mg/1OralNovartis Pharmaceuticals Corporation2015-03-30Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIV8G4MOF2V9
CAS number201530-41-8
WeightAverage: 373.3615
Monoisotopic: 373.106255983
Chemical FormulaC21H15N3O4
InChI KeyBOFQWVMAQOTZIW-UHFFFAOYSA-N
InChI
InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)
IUPAC Name
4-[bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid
SMILES
OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Pharmacology
IndicationFor the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.
Structured Indications
PharmacodynamicsDeferasirox is an orally active chelator that is selective for iron (as Fe3+). It is a tridentate ligand that binds iron with high affinity in a 2:1 ratio. Although deferasirox has very low affinity for zinc and copper there are variable decreases in the serum concentration of these trace metals after the administration of deferasirox. The clinical significance of these decreases is uncertain.
Mechanism of actionTwo molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.
TargetKindPharmacological actionActionsOrganismUniProt ID
IronSmall moleculeyes
chelator
Humannot applicabledetails
Related Articles
AbsorptionThe absolute bioavailability (AUC) of deferasirox tablets for oral suspension is 70% compared to an intravenous dose.
Volume of distribution
  • 14.37 ± 2.69 L
Protein bindingDeferasirox is highly (~99%) protein bound almost exclusively to serum albumin.
Metabolism

Hepatic. CYP450-catalyzed (oxidative) metabolism of deferasirox appears to be minor in humans (about 8%). Glucuronidation is the main metabolic pathway for deferasirox, with subsequent biliary excretion.

Route of eliminationDeferasirox and metabolites are primarily (84% of the dose) excreted in the feces. Renal excretion of deferasirox and metabolites is minimal (8% of the administered dose).
Half lifeThe mean elimination half-life ranged from 8 to 16 hours following oral administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Deferasirox.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Deferasirox.Experimental, Illicit
4-AndrostenedioneThe risk or severity of adverse effects can be increased when 4-Androstenedione is combined with Deferasirox.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Deferasirox.Experimental, Illicit
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Deferasirox.Approved
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Deferasirox.Approved
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Deferasirox.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Deferasirox.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Deferasirox.Approved
AcetovanilloneThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Deferasirox.Investigational
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Deferasirox.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Deferasirox.Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Deferasirox.Approved
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Deferasirox.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Deferasirox.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Deferasirox.Experimental
Alendronic acidThe risk or severity of adverse effects can be increased when Alendronic acid is combined with Deferasirox.Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Deferasirox.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Deferasirox.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Deferasirox.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Deferasirox.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Deferasirox.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Deferasirox.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Deferasirox.Approved, Withdrawn
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational
Aluminum hydroxideThe therapeutic efficacy of Deferasirox can be decreased when used in combination with Aluminum hydroxide.Approved
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Deferasirox.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Deferasirox.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Deferasirox.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Deferasirox.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Deferasirox.Approved
AmiodaroneThe serum concentration of Amiodarone can be decreased when it is combined with Deferasirox.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Deferasirox.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Deferasirox.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Deferasirox.Approved
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Deferasirox.Approved
AnagrelideThe serum concentration of Anagrelide can be increased when it is combined with Deferasirox.Approved
AncrodThe risk or severity of adverse effects can be increased when Ancrod is combined with Deferasirox.Investigational
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Deferasirox.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Deferasirox.Investigational
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Deferasirox.Approved
Antithrombin III humanThe risk or severity of adverse effects can be increased when Antithrombin III human is combined with Deferasirox.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Deferasirox.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Deferasirox.Approved, Investigational
AprepitantThe serum concentration of Aprepitant can be decreased when it is combined with Deferasirox.Approved, Investigational
ArdeparinThe risk or severity of adverse effects can be increased when Ardeparin is combined with Deferasirox.Approved, Withdrawn
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Deferasirox.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Deferasirox.Approved
ASA404The serum concentration of ASA404 can be increased when it is combined with Deferasirox.Investigational
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Deferasirox.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Deferasirox.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Deferasirox.Approved, Investigational
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Deferasirox.Approved
AV650The serum concentration of AV650 can be increased when it is combined with Deferasirox.Approved, Investigational
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Deferasirox.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Deferasirox.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Deferasirox.Withdrawn
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Deferasirox.Approved
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Deferasirox.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Deferasirox.Approved, Investigational
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Deferasirox.Investigational
BecaplerminThe risk or severity of adverse effects can be increased when Becaplermin is combined with Deferasirox.Approved, Investigational
BeclomethasoneThe risk or severity of adverse effects can be increased when Beclomethasone is combined with Deferasirox.Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Deferasirox.Approved, Investigational
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Deferasirox.Approved
BendamustineThe serum concentration of Bendamustine can be increased when it is combined with Deferasirox.Approved, Investigational
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Deferasirox.Withdrawn
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Deferasirox.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Deferasirox.Approved
BeraprostThe serum concentration of Beraprost can be increased when it is combined with Deferasirox.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Deferasirox.Approved, Vet Approved
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Deferasirox.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Deferasirox.Investigational
BexaroteneThe serum concentration of Bexarotene can be decreased when it is combined with Deferasirox.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Deferasirox.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Deferasirox.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Deferasirox.Approved
BivalirudinThe risk or severity of adverse effects can be increased when Bivalirudin is combined with Deferasirox.Approved, Investigational
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Deferasirox.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Deferasirox.Approved, Investigational
BosentanThe serum concentration of Bosentan can be decreased when it is combined with Deferasirox.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Deferasirox.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Deferasirox.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Deferasirox.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Deferasirox.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Deferasirox.Approved
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Deferasirox.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Deferasirox.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Deferasirox.Investigational
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Deferasirox.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Deferasirox.Approved, Investigational
BuprenorphineThe serum concentration of Buprenorphine can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Deferasirox.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Deferasirox.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Deferasirox.Approved, Investigational
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Deferasirox.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Deferasirox.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Deferasirox.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Deferasirox.Approved
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Deferasirox.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Deferasirox.Approved
CarbamazepineThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Deferasirox.Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Deferasirox.Approved
CarmustineThe serum concentration of Carmustine can be increased when it is combined with Deferasirox.Approved
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Deferasirox.Approved, Vet Approved, Withdrawn
CarvedilolThe serum concentration of Carvedilol can be decreased when it is combined with Deferasirox.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Deferasirox.Experimental
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Deferasirox.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Deferasirox.Approved, Vet Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Deferasirox.Withdrawn
CertoparinThe risk or severity of adverse effects can be increased when Certoparin is combined with Deferasirox.Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Deferasirox.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Deferasirox.Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Deferasirox.Approved, Illicit
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Deferasirox.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Deferasirox.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Deferasirox.Approved, Nutraceutical
CholestyramineThe serum concentration of Deferasirox can be decreased when it is combined with Cholestyramine.Approved
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Deferasirox.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be decreased when it is combined with Deferasirox.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Deferasirox.Approved
CinnarizineThe serum concentration of Cinnarizine can be increased when it is combined with Deferasirox.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Deferasirox.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be decreased when it is combined with Deferasirox.Approved
Citric AcidThe risk or severity of adverse effects can be increased when Citric Acid is combined with Deferasirox.Nutraceutical, Vet Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Deferasirox.Approved
ClenbuterolThe serum concentration of Clenbuterol can be increased when it is combined with Deferasirox.Approved, Vet Approved
ClevidipineThe serum concentration of Clevidipine can be increased when it is combined with Deferasirox.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Deferasirox.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Deferasirox.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Deferasirox.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Deferasirox.Approved
ClodronateThe risk or severity of adverse effects can be increased when Clodronate is combined with Deferasirox.Approved, Investigational, Vet Approved
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Deferasirox.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Deferasirox.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Deferasirox.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Deferasirox.Approved
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Deferasirox.Approved
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Deferasirox.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Deferasirox.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Deferasirox.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Deferasirox.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Deferasirox.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Deferasirox.Approved
ColesevelamThe serum concentration of Deferasirox can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Deferasirox can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Conivaptan can be decreased when it is combined with Deferasirox.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Deferasirox.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Deferasirox.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Deferasirox.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Deferasirox.Investigational
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Deferasirox.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Deferasirox.Approved, Investigational
D-LimoneneThe risk or severity of adverse effects can be increased when D-Limonene is combined with Deferasirox.Investigational
Dabigatran etexilateThe risk or severity of adverse effects can be increased when Dabigatran etexilate is combined with Deferasirox.Approved
DabrafenibThe serum concentration of Dabrafenib can be decreased when it is combined with Deferasirox.Approved
DacarbazineThe serum concentration of Dacarbazine can be increased when it is combined with Deferasirox.Approved, Investigational
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Deferasirox.Approved
DalteparinThe risk or severity of adverse effects can be increased when Dalteparin is combined with Deferasirox.Approved
DanaparoidThe risk or severity of adverse effects can be increased when Danaparoid is combined with Deferasirox.Approved, Withdrawn
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Deferasirox.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Deferasirox.Approved
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Deferasirox.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Deferasirox.Approved, Investigational
DarunavirThe serum concentration of Darunavir can be decreased when it is combined with Deferasirox.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Deferasirox.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Deferasirox.Approved
dehydroepiandrosterone sulfateThe risk or severity of adverse effects can be increased when dehydroepiandrosterone sulfate is combined with Deferasirox.Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Deferasirox.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Deferasirox.Approved
DesirudinThe risk or severity of adverse effects can be increased when Desirudin is combined with Deferasirox.Approved
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Deferasirox.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Deferasirox.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Deferasirox.Experimental, Vet Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Deferasirox.Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Deferasirox.Vet Approved
DexfenfluramineThe serum concentration of Dexfenfluramine can be increased when it is combined with Deferasirox.Approved, Illicit, Withdrawn
DextranThe risk or severity of adverse effects can be increased when Dextran is combined with Deferasirox.Approved, Vet Approved
Dextran 40The risk or severity of adverse effects can be increased when Dextran 40 is combined with Deferasirox.Approved
Dextran 70The risk or severity of adverse effects can be increased when Dextran 70 is combined with Deferasirox.Approved
Dextran 75The risk or severity of adverse effects can be increased when Dextran 75 is combined with Deferasirox.Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Deferasirox.Approved
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Deferasirox.Approved, Illicit, Withdrawn
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Deferasirox.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Deferasirox.Approved, Vet Approved
DicoumarolThe risk or severity of adverse effects can be increased when Dicoumarol is combined with Deferasirox.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Deferasirox.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Deferasirox.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Deferasirox.Approved
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Deferasirox.Approved
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Deferasirox.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Deferasirox.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Deferasirox.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Deferasirox.Approved
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Deferasirox.Approved
DinoprostoneThe serum concentration of Dinoprostone can be increased when it is combined with Deferasirox.Approved
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Deferasirox.Approved
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Deferasirox.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Deferasirox.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Deferasirox.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Deferasirox.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Deferasirox.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Deferasirox.Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Deferasirox.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Deferasirox.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Deferasirox.Approved, Investigational
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Deferasirox.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Deferasirox.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Deferasirox.Approved
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Deferasirox.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Deferasirox.Approved, Investigational
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Deferasirox.Investigational
E6201The risk or severity of adverse effects can be increased when E6201 is combined with Deferasirox.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Deferasirox.Investigational
Edetic AcidThe risk or severity of adverse effects can be increased when Edetic Acid is combined with Deferasirox.Approved, Vet Approved
EdoxabanThe risk or severity of adverse effects can be increased when Edoxaban is combined with Deferasirox.Approved
EfavirenzThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Deferasirox.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Deferasirox.Approved
EltrombopagThe serum concentration of Eltrombopag can be increased when it is combined with Deferasirox.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Deferasirox.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Deferasirox.Approved, Vet Approved
EnoxaparinThe risk or severity of adverse effects can be increased when Enoxaparin is combined with Deferasirox.Approved
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Deferasirox.Approved
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Deferasirox.Approved, Investigational
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Deferasirox.Approved
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Deferasirox.Approved
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Deferasirox.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Deferasirox.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Deferasirox.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Deferasirox.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Deferasirox.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Deferasirox.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Deferasirox.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.Approved, Investigational
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Deferasirox.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Deferasirox.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Deferasirox.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Deferasirox.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Deferasirox.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Deferasirox.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Deferasirox.Approved, Investigational
EthanolThe serum concentration of Ethanol can be decreased when it is combined with Deferasirox.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Deferasirox.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Deferasirox.Approved
Ethyl biscoumacetateThe risk or severity of adverse effects can be increased when Ethyl biscoumacetate is combined with Deferasirox.Withdrawn
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Deferasirox.Approved, Illicit
Etidronic acidThe risk or severity of adverse effects can be increased when Etidronic acid is combined with Deferasirox.Approved
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Deferasirox.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Deferasirox.Approved
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Deferasirox.Approved, Investigational
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Deferasirox.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Deferasirox.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Deferasirox.Approved
Evening primrose oilThe risk or severity of adverse effects can be increased when Evening primrose oil is combined with Deferasirox.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Deferasirox.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Deferasirox.Approved, Investigational
exisulindThe risk or severity of adverse effects can be increased when exisulind is combined with Deferasirox.Investigational
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Deferasirox.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Deferasirox.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Deferasirox.Approved, Investigational
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Deferasirox.Approved
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Deferasirox.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Deferasirox.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Deferasirox.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Deferasirox.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Deferasirox.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Deferasirox.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Deferasirox.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Deferasirox.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Deferasirox.Approved
FluindioneThe risk or severity of adverse effects can be increased when Fluindione is combined with Deferasirox.Investigational
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Deferasirox.Approved, Vet Approved
FlunarizineThe serum concentration of Flunarizine can be increased when it is combined with Deferasirox.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Deferasirox.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
FlunixinThe risk or severity of adverse effects can be increased when Flunixin is combined with Deferasirox.Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Deferasirox.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Deferasirox.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Deferasirox.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Deferasirox.Approved
FluorouracilThe serum concentration of Fluorouracil can be increased when it is combined with Deferasirox.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Deferasirox.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Deferasirox.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Deferasirox.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Deferasirox.Approved, Investigational
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Deferasirox.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Deferasirox.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Deferasirox.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Deferasirox.Approved
FluvoxamineThe serum concentration of Fluvoxamine can be increased when it is combined with Deferasirox.Approved, Investigational
FondaparinuxThe risk or severity of adverse effects can be increased when Fondaparinux is combined with Deferasirox.Investigational
Fondaparinux sodiumThe risk or severity of adverse effects can be increased when Fondaparinux sodium is combined with Deferasirox.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Deferasirox.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Fosamprenavir can be decreased when it is combined with Deferasirox.Approved
FosphenytoinThe serum concentration of Deferasirox can be decreased when it is combined with Fosphenytoin.Approved
FrovatriptanThe serum concentration of Frovatriptan can be increased when it is combined with Deferasirox.Approved, Investigational
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Deferasirox.Approved, Investigational
GabexateThe risk or severity of adverse effects can be increased when Gabexate is combined with Deferasirox.Investigational
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Deferasirox.Approved
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Deferasirox.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Deferasirox.Approved
GenisteinThe serum concentration of Genistein can be increased when it is combined with Deferasirox.Investigational
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Deferasirox.Approved
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Deferasirox.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Deferasirox.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Deferasirox.Withdrawn
GuanabenzThe serum concentration of Guanabenz can be increased when it is combined with Deferasirox.Approved
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Deferasirox.Approved, Investigational
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Deferasirox.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Deferasirox.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Deferasirox.Approved, Vet Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Deferasirox.Investigational
HeparinThe risk or severity of adverse effects can be increased when Heparin is combined with Deferasirox.Approved, Investigational
HesperetinThe serum concentration of Hesperetin can be increased when it is combined with Deferasirox.Approved
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Deferasirox.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Deferasirox.Investigational
HirulogThe risk or severity of adverse effects can be increased when Hirulog is combined with Deferasirox.Experimental
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Deferasirox.Approved
HMPL-004The risk or severity of adverse effects can be increased when HMPL-004 is combined with Deferasirox.Investigational
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Deferasirox.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Deferasirox.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Deferasirox.Approved
IbandronateThe risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.Approved, Investigational
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Deferasirox.Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Deferasirox.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Deferasirox.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Deferasirox.Approved
idraparinuxThe risk or severity of adverse effects can be increased when idraparinux is combined with Deferasirox.Investigational
IfosfamideThe serum concentration of Ifosfamide can be decreased when it is combined with Deferasirox.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Deferasirox.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Deferasirox.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Deferasirox.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Deferasirox.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Deferasirox.Approved
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Deferasirox.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Deferasirox.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Deferasirox.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Deferasirox.Withdrawn
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.Approved
IrbesartanThe serum concentration of Irbesartan can be increased when it is combined with Deferasirox.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Deferasirox.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Deferasirox.Approved, Investigational
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Deferasirox.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Deferasirox.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Deferasirox.Withdrawn
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Deferasirox.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Deferasirox.Investigational
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Deferasirox.Approved
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Deferasirox.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Deferasirox.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Deferasirox.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Deferasirox.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Deferasirox.Experimental
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Deferasirox.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Deferasirox.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Deferasirox.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Deferasirox.Approved
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Deferasirox.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Deferasirox.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Deferasirox.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Deferasirox.Approved
LepirudinThe risk or severity of adverse effects can be increased when Lepirudin is combined with Deferasirox.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Deferasirox.Approved, Investigational
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Deferasirox.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Deferasirox.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Deferasirox.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Deferasirox.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Deferasirox.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Deferasirox.Approved, Investigational
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Deferasirox.Approved
LicofeloneThe serum concentration of Licofelone can be increased when it is combined with Deferasirox.Investigational
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Deferasirox.Investigational
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Deferasirox.Approved
LomefloxacinThe serum concentration of Lomefloxacin can be increased when it is combined with Deferasirox.Approved
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Deferasirox.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Deferasirox.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Deferasirox.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Deferasirox.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Deferasirox.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Deferasirox.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Deferasirox.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Deferasirox.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Deferasirox.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Deferasirox.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Deferasirox.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Deferasirox.Approved
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Deferasirox.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Deferasirox.Approved
MalathionThe serum concentration of Malathion can be increased when it is combined with Deferasirox.Approved, Investigational
MaprotilineThe serum concentration of Maprotiline can be increased when it is combined with Deferasirox.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Deferasirox.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Deferasirox.Approved
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Deferasirox.Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Deferasirox.Approved, Vet Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Deferasirox.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Deferasirox.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Deferasirox.Approved
Mefenamic acidThe serum concentration of Mefenamic acid can be increased when it is combined with Deferasirox.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Deferasirox.Approved
MelatoninThe serum concentration of Melatonin can be increased when it is combined with Deferasirox.Approved, Nutraceutical, Vet Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Deferasirox.Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Deferasirox.Approved, Vet Approved
MenadioneThe serum concentration of Menadione can be increased when it is combined with Deferasirox.Approved, Nutraceutical
MephenytoinThe serum concentration of Mephenytoin can be increased when it is combined with Deferasirox.Investigational, Withdrawn
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Deferasirox.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox.Withdrawn
MethadoneThe serum concentration of Methadone can be decreased when it is combined with Deferasirox.Approved
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Deferasirox.Illicit, Withdrawn
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Deferasirox.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Deferasirox.Approved, Vet Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Deferasirox.Approved
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Deferasirox.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Deferasirox.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Deferasirox.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Deferasirox.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Deferasirox.Approved, Illicit
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Deferasirox.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Deferasirox.Approved
MirtazapineThe serum concentration of Mirtazapine can be decreased when it is combined with Deferasirox.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Deferasirox.Investigational
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Deferasirox.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox.Approved, Vet Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Deferasirox.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Deferasirox.Approved, Investigational
muraglitazarThe serum concentration of muraglitazar can be increased when it is combined with Deferasirox.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Deferasirox.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Deferasirox.Approved
NadroparinThe risk or severity of adverse effects can be increased when Nadroparin is combined with Deferasirox.Approved
NafamostatThe risk or severity of adverse effects can be increased when Nafamostat is combined with Deferasirox.Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Deferasirox.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Deferasirox.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
NaproxenThe serum concentration of Naproxen can be increased when it is combined with Deferasirox.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Deferasirox.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Deferasirox.Investigational
NCX 4016The risk or severity of adverse effects can be increased when NCX 4016 is combined with Deferasirox.Investigational
NefazodoneThe serum concentration of Nefazodone can be decreased when it is combined with Deferasirox.Approved, Withdrawn
NelfinavirThe serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox.Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Deferasirox.Approved
NevirapineThe serum concentration of Nevirapine can be decreased when it is combined with Deferasirox.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Deferasirox.Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Deferasirox.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Deferasirox.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Deferasirox.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Deferasirox.Approved, Investigational
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Deferasirox.Approved
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Deferasirox.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Deferasirox.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Deferasirox.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Deferasirox.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Deferasirox.Approved
Nitric OxideThe serum concentration of Nitric Oxide can be increased when it is combined with Deferasirox.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Nitroaspirin is combined with Deferasirox.Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Deferasirox.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Deferasirox.Approved
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Deferasirox.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Deferasirox.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Deferasirox.Approved
Oleoyl estroneThe risk or severity of adverse effects can be increased when Oleoyl estrone is combined with Deferasirox.Investigational
OlodaterolThe serum concentration of Olodaterol can be increased when it is combined with Deferasirox.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Deferasirox.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Deferasirox.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Deferasirox.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Deferasirox.Approved
OrgoteinThe risk or severity of adverse effects can be increased when Orgotein is combined with Deferasirox.Vet Approved
OrphenadrineThe serum concentration of Orphenadrine can be decreased when it is combined with Deferasirox.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Deferasirox.Approved
OtamixabanThe risk or severity of adverse effects can be increased when Otamixaban is combined with Deferasirox.Investigational
OxaliplatinThe serum concentration of Oxaliplatin can be increased when it is combined with Deferasirox.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Deferasirox.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Deferasirox.Approved
OxtriphyllineThe serum concentration of Oxtriphylline can be increased when it is combined with Deferasirox.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Deferasirox.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Deferasirox.Withdrawn
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Deferasirox.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Deferasirox.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Deferasirox.Approved, Investigational
PamidronateThe risk or severity of adverse effects can be increased when Pamidronate is combined with Deferasirox.Approved
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Deferasirox.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Deferasirox.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Deferasirox.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Deferasirox.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Deferasirox.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Deferasirox.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Deferasirox.Approved
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Deferasirox.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Deferasirox.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deferasirox.Approved
PentoxifyllineThe serum concentration of Pentoxifylline can be increased when it is combined with Deferasirox.Approved, Investigational
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Deferasirox.Approved
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Deferasirox.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Deferasirox.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Deferasirox.Approved, Investigational
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Deferasirox.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Deferasirox.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Deferasirox.Withdrawn
PhenindioneThe risk or severity of adverse effects can be increased when Phenindione is combined with Deferasirox.Approved
PhenobarbitalThe serum concentration of Deferasirox can be decreased when it is combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Deferasirox.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Deferasirox.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Deferasirox.Approved, Vet Approved
PhenytoinThe serum concentration of Deferasirox can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Deferasirox.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Deferasirox.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Deferasirox.Withdrawn
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Deferasirox.Approved, Investigational
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Deferasirox.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Deferasirox.Investigational
PiroxicamThe serum concentration of Piroxicam can be increased when it is combined with Deferasirox.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Deferasirox.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Deferasirox.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Deferasirox.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Deferasirox.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Deferasirox.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Deferasirox.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Deferasirox.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Deferasirox.Approved, Vet Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Deferasirox.Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Deferasirox.Experimental
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Deferasirox.Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Deferasirox.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Deferasirox.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Deferasirox.Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Deferasirox.Approved, Investigational
Protein CThe risk or severity of adverse effects can be increased when Protein C is combined with Deferasirox.Approved
Protein S humanThe risk or severity of adverse effects can be increased when Protein S human is combined with Deferasirox.Approved
ProtocatechualdehydeThe risk or severity of adverse effects can be increased when Protocatechualdehyde is combined with Deferasirox.Approved
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Deferasirox.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Deferasirox.Approved
QuazepamThe serum concentration of Quazepam can be decreased when it is combined with Deferasirox.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Deferasirox.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Deferasirox.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Deferasirox.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Deferasirox.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Deferasirox.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Deferasirox.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Deferasirox.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Deferasirox.Approved, Investigational
RasagilineThe serum concentration of Rasagiline can be increased when it is combined with Deferasirox.Approved
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Deferasirox.Approved
RepaglinideThe serum concentration of Repaglinide can be increased when it is combined with Deferasirox.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Deferasirox.Experimental, Investigational
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Deferasirox.Approved
ReviparinThe risk or severity of adverse effects can be increased when Reviparin is combined with Deferasirox.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Deferasirox.Approved
RifampicinThe serum concentration of Deferasirox can be decreased when it is combined with Rifampicin.Approved
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Deferasirox.Approved
RiluzoleThe serum concentration of Riluzole can be increased when it is combined with Deferasirox.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Deferasirox.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Deferasirox.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Deferasirox.Approved
RisedronateThe risk or severity of adverse effects can be increased when Risedronate is combined with Deferasirox.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Deferasirox.Approved, Investigational
RitonavirThe serum concentration of Deferasirox can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Deferasirox.Approved
RizatriptanThe serum concentration of Rizatriptan can be increased when it is combined with Deferasirox.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Deferasirox.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Deferasirox.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Deferasirox.Approved, Investigational
RopiniroleThe serum concentration of Ropinirole can be decreased when it is combined with Deferasirox.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Deferasirox.Approved
RosiglitazoneThe serum concentration of Rosiglitazone can be increased when it is combined with Deferasirox.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Deferasirox.Approved
RotigotineThe serum concentration of Rotigotine can be decreased when it is combined with Deferasirox.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Deferasirox.Approved, Withdrawn
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Deferasirox.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Deferasirox.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Deferasirox.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Deferasirox.Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Deferasirox.Approved
SaquinavirThe serum concentration of Saquinavir can be decreased when it is combined with Deferasirox.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Deferasirox.Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Deferasirox.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Deferasirox.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Deferasirox.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Deferasirox.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Deferasirox.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Deferasirox.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Deferasirox.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Deferasirox.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Deferasirox.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Deferasirox.Approved, Investigational
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Deferasirox.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Deferasirox.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Deferasirox.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Deferasirox.Approved
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Deferasirox.Investigational
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Deferasirox.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Deferasirox.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Deferasirox.Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Deferasirox.Approved
SulodexideThe risk or severity of adverse effects can be increased when Sulodexide is combined with Deferasirox.Approved, Investigational
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Deferasirox.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Deferasirox.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Deferasirox.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Deferasirox.Approved
TacrineThe serum concentration of Tacrine can be increased when it is combined with Deferasirox.Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Deferasirox.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Deferasirox.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Deferasirox.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Deferasirox.Approved, Investigational
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Deferasirox.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Deferasirox.Experimental
TazaroteneThe serum concentration of Tazarotene can be increased when it is combined with Deferasirox.Approved, Investigational
Technetium tc 99m etidronateThe risk or severity of adverse effects can be increased when Technetium tc 99m etidronate is combined with Deferasirox.Approved
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Technetium Tc-99m Medronate is combined with Deferasirox.Approved
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Deferasirox.Approved
TelithromycinThe serum concentration of Telithromycin can be decreased when it is combined with Deferasirox.Approved
TemafloxacinThe serum concentration of Temafloxacin can be increased when it is combined with Deferasirox.Withdrawn
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Deferasirox.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Deferasirox.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Deferasirox.Approved
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Deferasirox.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Tepoxalin is combined with Deferasirox.Vet Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Deferasirox.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Deferasirox.Withdrawn
TeriflunomideThe risk or severity of adverse effects can be increased when Teriflunomide is combined with Deferasirox.Approved
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Deferasirox.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Deferasirox.Approved, Investigational
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ThalidomideThe serum concentration of Thalidomide can be increased when it is combined with Deferasirox.Approved, Investigational, Withdrawn
TheobromineThe serum concentration of Theobromine can be increased when it is combined with Deferasirox.Approved
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Deferasirox.Approved
ThiabendazoleThe serum concentration of Thiabendazole can be increased when it is combined with Deferasirox.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Deferasirox.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Deferasirox.Approved
ThiothixeneThe serum concentration of Thiothixene can be increased when it is combined with Deferasirox.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Deferasirox.Approved
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Deferasirox.Approved
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Deferasirox.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Deferasirox.Approved
TiludronateThe risk or severity of adverse effects can be increased when Tiludronate is combined with Deferasirox.Approved, Vet Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Deferasirox.Approved, Investigational
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Deferasirox.Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Deferasirox.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Deferasirox.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Deferasirox.Approved
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Deferasirox.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Deferasirox.Approved, Investigational
TolbutamideThe serum concentration of Tolbutamide can be increased when it is combined with Deferasirox.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Deferasirox.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Deferasirox.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Deferasirox.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Deferasirox.Approved
TorasemideThe serum concentration of Torasemide can be increased when it is combined with Deferasirox.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Deferasirox.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Deferasirox.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Deferasirox.Approved, Investigational
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Deferasirox.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Deferasirox.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Deferasirox.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Deferasirox.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Deferasirox.Approved, Vet Approved
TriamtereneThe serum concentration of Triamterene can be increased when it is combined with Deferasirox.Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Deferasirox.Approved
TrifluoperazineThe serum concentration of Trifluoperazine can be increased when it is combined with Deferasirox.Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Deferasirox.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Deferasirox.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Deferasirox.Approved
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Deferasirox.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Deferasirox.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Deferasirox.Approved
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Deferasirox.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Deferasirox.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Deferasirox.Investigational, Withdrawn
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Deferasirox.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Deferasirox.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Deferasirox.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Deferasirox.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Deferasirox.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Deferasirox.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Deferasirox.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Deferasirox.Investigational
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Deferasirox.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Deferasirox.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Deferasirox.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Deferasirox.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Deferasirox.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Deferasirox.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Deferasirox.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Deferasirox.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Deferasirox.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Deferasirox.Approved
XimelagatranThe risk or severity of adverse effects can be increased when Ximelagatran is combined with Deferasirox.Approved, Investigational, Withdrawn
Ym150The risk or severity of adverse effects can be increased when Ym150 is combined with Deferasirox.Investigational
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Deferasirox.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Deferasirox.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Deferasirox.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Deferasirox.Approved, Illicit, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Deferasirox.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Deferasirox.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Deferasirox.Approved, Investigational, Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Deferasirox.Approved
Zoledronic acidThe risk or severity of adverse effects can be increased when Zoledronic acid is combined with Deferasirox.Approved
ZolmitriptanThe serum concentration of Zolmitriptan can be increased when it is combined with Deferasirox.Approved, Investigational
ZolpidemThe serum concentration of Zolpidem can be decreased when it is combined with Deferasirox.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Deferasirox.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Deferasirox.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Deferasirox.Approved
Food Interactions
  • Dispersion in carbonated drinks or milk is not recommended due to foaming and slow dispersion, respectively.
  • Food causes inconsistent increases in the bioavailability of this product.
  • Tablets should be completely dispersed in water, orange juice or apple juice and the resulting suspension should be ingested immediately (after swallowing the suspension, any residue should be resuspended in a small volume of liquid and swallowed).
  • Tablets should be taken on an empty stomach at least 30 minutes before a meal, preferably at the same time everyday.
References
Synthesis Reference

Rajendra Suryabhan Patil, Kishore Charugundla, Praveen Kumar Neela, Nitin Sharadchandra Pradhan, Jon Valgeirsson, “SUBSTANTIALLY PURE DEFERASIROX AND PROCESSES FOR THE PREPARATION THEREOF.” U.S. Patent US20110171138, issued July 14, 2011.

US20110171138
General ReferencesNot Available
External Links
ATC CodesV03AC03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.993
Blood Brain Barrier+0.8508
Caco-2 permeable+0.5089
P-glycoprotein substrateNon-substrate0.7808
P-glycoprotein inhibitor INon-inhibitor0.894
P-glycoprotein inhibitor IINon-inhibitor0.8431
Renal organic cation transporterNon-inhibitor0.8708
CYP450 2C9 substrateNon-substrate0.7212
CYP450 2D6 substrateNon-substrate0.8686
CYP450 3A4 substrateNon-substrate0.6466
CYP450 1A2 substrateNon-inhibitor0.5802
CYP450 2C9 inhibitorNon-inhibitor0.7105
CYP450 2D6 inhibitorNon-inhibitor0.8221
CYP450 2C19 inhibitorNon-inhibitor0.5918
CYP450 3A4 inhibitorNon-inhibitor0.8179
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5717
Ames testNon AMES toxic0.6607
CarcinogenicityNon-carcinogens0.8519
BiodegradationNot ready biodegradable0.9524
Rat acute toxicity2.1119 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9684
hERG inhibition (predictor II)Non-inhibitor0.9072
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tablet, film coatedOral180 mg
Tablet, film coatedOral360 mg
Tablet, film coatedOral90 mg
Tablet, for suspensionOral125 mg
Tablet, for suspensionOral125 mg/1
Tablet, for suspensionOral250 mg/1
Tablet, for suspensionOral250 mg
Tablet, for suspensionOral500 mg
Tablet, for suspensionOral500 mg/1
TabletOral180 mg
TabletOral360 mg
TabletOral90 mg
Tablet, film coatedOral180 mg/1
Tablet, film coatedOral360 mg/1
Tablet, film coatedOral90 mg/1
Prices
Unit descriptionCostUnit
Exjade 500 mg tablet78.61USD tablet
Exjade 250 mg tablet39.3USD tablet
Exjade 125 mg tablet19.65USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2255951 No2006-10-102017-06-24Canada
US6465504 No1999-04-052019-04-05Us
US6596750 No1997-06-242017-06-24Us
US9283209 No2014-11-212034-11-21Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point116-117 °CNot Available
water solubility0.038 mg/mL at 37 °CYALKOWSKY,SH & DANNENFELSER,RM (1992)
logP3.52HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.0343 mg/mLALOGPS
logP4.01ALOGPS
logP4.74ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)4.55ChemAxon
pKa (Strongest Basic)0.19ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area108.47 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity125.32 m3·mol-1ChemAxon
Polarizability38.52 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenyl-1,3,4-triazoles. These are organic compounds containing a 1,3,4-triazole substituted by a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassTriazoles
Direct ParentPhenyl-1,3,4-triazoles
Alternative Parents
Substituents
  • Phenyl-1,3,4-triazole
  • Phenyl-1,2,4-triazole
  • Aminobenzoic acid or derivatives
  • Aminobenzoic acid
  • Benzoic acid
  • Benzoic acid or derivatives
  • Benzoyl
  • Phenol
  • Benzenoid
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

1. Iron
Kind
Small molecule
Organism
Human
Pharmacological action
yes
Actions
chelator
References
  1. Wang T, Gao C, Chen BA: [Deferasirox--a new oral iron chelator--review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Oct;18(5):1359-64. [PubMed:21129294 ]
  2. Ibrahim AS, Spellberg B, Edwards J Jr: Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008 Dec;21(6):620-5. doi: 10.1097/QCO.0b013e3283165fd1. [PubMed:18978530 ]
  3. Devanur LD, Evans RW, Evans PJ, Hider RC: Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem J. 2008 Jan 15;409(2):439-47. [PubMed:17919118 ]
  4. Lebitasy M, Ampe E, Hecq JD, Karmani L, Nick H, Galanti L: Ability of deferasirox to bind iron during measurement of iron. Clin Chem Lab Med. 2010 Mar;48(3):427-9. doi: 10.1515/CCLM.2010.080. [PubMed:20170398 ]
  5. Yang LP, Keam SJ, Keating GM: Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs. 2007;67(15):2211-30. [PubMed:17927285 ]
  6. Choudhry VP, Naithani R: Current status of iron overload and chelation with deferasirox. Indian J Pediatr. 2007 Aug;74(8):759-64. [PubMed:17785900 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Skerjanec A, Wang J, Maren K, Rojkjaer L: Investigation of the pharmacokinetic interactions of deferasirox, a once-daily oral iron chelator, with midazolam, rifampin, and repaglinide in healthy volunteers. J Clin Pharmacol. 2010 Feb;50(2):205-13. doi: 10.1177/0091270009340418. Epub 2009 Nov 25. [PubMed:19940232 ]
Comments
comments powered by Disqus
Drug created on August 29, 2007 13:21 / Updated on December 10, 2016 03:16